Medicare Spending Implications for Semaglutide Under Voluntary Price Agreements

This study compares expected total Medicare spending on semaglutide in 2027 under voluntary price agreement participation vs nonparticipation and estimates beneficiaries eligible for expanded obesity-indication coverage whose treatment costs could be offset with savings from the agreement.

Corresponding Author: Stacie B. Dusetzina, PhD, Vanderbilt University School of Medicine, 2525 West End Ave, Ste 1209, Nashville, TN 37203 (s.dusetzina@vanderbilt.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.